Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Indivior Pharmaceuticals Inc. | AEF0117 | Cannabis-Related Disorders (CrD) | Phase 2b | Data Released | Oral | Psychiatric |
| Infinity Pharmaceuticals Inc. | COPIKTRA (duvelisib) | Rheumatoid arthritis | Phase 2 | Trial Discontinued | oral | Immunology: Anti-TNF |
| Infinity Pharmaceuticals Inc. | COPIKTRA (duvelisib) - (DYNAMO) | Indolent non-Hodgkin lymphoma | Phase 2 | Trial Discontinued | Oral | Oncology |
| Infinity Pharmaceuticals Inc. | MARIO-P Platform | Ovarian cancer, NSCLC, Soft tissue sarcoma, prostate cancer | Phase 2 | Intravenous | Oncology | |
| Infinity Pharmaceuticals Inc. | Eganelisib (IPI-549) + TECENTRIQ (atezolizumab) and ABRAXANE (nab-paclitaxel) and IPI-549 + TECENTRIQ (atezolizumab) and AVASTIN (Bevacizumab) - (MARIO-3) | Front-line triple negative breast cancer (TNBC); Renal cell cancer (RCC) | Phase 2 | Intravenous | Oncology | |
| Infinity Pharmaceuticals Inc. | Eganelisib + pembrolizumab - (MARIO-8) | Squamous Cell Carcinoma of the Head and Neck (SSCHN) | Phase 2 | Ongoing | Intravenous | Oncology |
| InflaRx N.V. | Vilobelimab (IFX-1) - (IXCHANGE) | ANCA-associated Vasculitis (AAV) | Phase 2 | Data Released | Intravenous | Immunology |
| InflaRx N.V. | Izicopan (INF904) | Chronic Autoimmune and Inflammatory Diseases | Phase 2a | Data Released | Oral | Immunology |
